Hyundai Bioscience announced on April 25th that its clinical development plan of oral “Niclosamide Metabolic Anticancer Drug” targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost all cancer types and cause intractable cancers such cases found in ovarian cancer, uterine cancer, esophageal cancer, etc. The p53 gene […]
Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID) system powered by Tidepool. The twiist AID system, which will be commercialized by Sequel Med […]
Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The patent application applies to APEX’s uniquely formulated capsule which will be used for PATHFINDER-52 and SUMMIT-90 phase 2b clinical trials and in […]
